* PMV Pharmaceuticals Inc PMVP.OQ PMVP.O is expected
to show
no change in quarterly revenue when it reports results on May 8
(estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for PMV Pharmaceuticals Inc
is for
a loss of 36 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had risen by
about 1.5%
in the last three months.
* Wall Street's median 12-month price target for PMV
Pharmaceuticals Inc is $6.00, above its last closing price
of $1.99.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.38 -0.39 -0.31 Beat 19.7
Jun. 30 2023 -0.45 -0.45 -0.34 Beat 23.8
Jun. 30 2023 -0.46 -0.47 -0.38 Beat 20
Mar. 31 2023 -0.44 -0.46 -0.42 Beat 8.4
Jan. -0.44 -0.44 -0.43 Beat 1.9
1 0001
Jan. 1 0001 -0.43 -0.42 -0.40 Beat 5.5
Jun. 30 2022 -0.42 -0.41 -0.38 Beat 6.9
Mar. 31 2022 -0.43 -0.40 -0.41 Missed -1.7
This summary was machine generated May 6 at 14:49 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)